LPCN - Lipocine announces plans to focus on treating CNS disorders shares rise ~5%

• Lipocine ( NASDAQ: LPCN ) on Monday said the company would now focus on applying its drug delivery technology to develop treatments for central nervous system (CNS) disorders.
• LPCN stock +4.7% to $0.52 in premarket trading.
• The company will use its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products, LPCN said in a statement .
• The initial focus for the company will be on the delivery of neuroactive steroids, which have been shown to impact CNS function.
• The company's CNS development portfolio includes LPCN 1154 for the treatment of postpartum depressoin, LPCN 2101 for women with epilepsy and some undisclosed candidates.
• LPCN said it would stop further investments in its programs for liver diseases and other disorders, and will advance them instead through partnerships.
• The company believes that its cash securities of $37.4M would be sufficient to support operations and capital expenditure until at least Sept. 30, 2023.

For further details see: